Biologics in Severe Asthma: Optimizing Therapeutic Selection and Patient Outcomes

Released On
December 14, 2020

Expires On
December 13, 2021

Media Type

Completion Time
60 minutes

Allergy & Immunology, Primary Care

Allergies, Asthma, Respiratory

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Annenberg Center for Health Sciences at Eisenhower.

This activity is supported in part by an independent education grant from Novartis Pharmaceuticals Corporation..

Credit Available

  • Physicians — maximum of 1.00 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity was developed for pulmonologists, allergists, immunologists, primary care physicians, and other healthcare professionals involved in the care of patients with severe asthma.

Program Overview

This case-based activity focuses on considerations, including phenotypes and biomarkers, in individualizing treatment with the 5 monoclonal antibodies currently approved for severe asthma in the United States. The role of shared decision-making is discussed as an approach to individualizing therapy and improving patient outcomes. Clinical criteria for assessing treatment response to biologic therapy and how to modify therapy when needed are also discussed.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the latest evidence regarding the pathophysiology of severe asthma
  • Explain the clinical implication of the latest scientific developments in the area of biologic therapies for the management of severe asthma
  • Differentiate biologic therapies currently available for the management of patients with severe asthma
  • Implement biologic therapy for a patient with severe asthma taking into account the latest available data and genetic factors


Reynold A. Panettieri, Jr., MD

Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Rutgers University
New Brunswick, New Jersey
Emeritus Professor of Medicine, University of Pennsylvania

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Disclosures of Conflicts of Interest


Reynold A. Panettieri, Jr., MD

  • Advisory Board: AstraZeneca, Equillium, RIFM
  • Research Support: AstraZeneca, Genentech, Johnson and Johnson, Maven, Medimmune, Novartis, Optikira, RIFM
  • Speakers Bureau: AstraZeneca, Genentech, Regeneron, Sanofi

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Gene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.


The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information

For CME questions please contact:

Continuing Education
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday